Category Archives: Non classé

Our study on the preclinical in vivo efficacy of Metavac®-RSV, an intranasal live-attenuated bivalent vaccine candidate against Respiratory Syncytial Virus and Human Metapneumovirus, has been published in Nature portfolio’s npj Vaccines. This study reports challenge studies performed on mice model showing that intranasal immunisation with Metavac®-RSV fully protects animals against infections with wild type HMPV and RSV, the main sources of bronchiolitis and viral pneumonia in children an...

Our spin-off Nexomis has developed a novel simulation method for generating connected differential expression signatures, based on a statistical framework that allows for adjustable levels of parametrization. This method directly addresses the issue of benchmarking data availability for connectivity-based drug repurposing approaches. This work was published in the journal Briefings in Bioinformatics (Oxford University press). It was elected article of the week by Drug Repurposing Research Collec...

We are proud to present our expertise and advancements in respiratory viral infection research using predictive in vitro human lung models.Emilie Laurent and Remi Pereira will present our latest study on SARS-CoV-2 and H1N1 Influenza infections in the AlveolAirâ„¢ model (Epithelix), in which primary human pneumocytes are co-cultured at the air-liquid interface with endothelial cells (poster session).Julien Fouret will give an oral presentation in Session 8 viral infections (June 21st) entitled Â...

Financed by the Auvergne-Rhône-Alpes Regional Innovation Fund and Bpifrance (R&D booster programme) and accredited by the Lyonbiopôle Auvergne-Rhône-Alpes health cluster, the public-private partnership program SURVIR has developed and validated an innovative automated platform for the rapid characterisation and quantification of a broad range of emerging and re-emerging respiratory pathogens. Based on a single multiplex analysis test, combined with statistical interpretation of the result...

VirNext is pleased to announce the launch of its new spin-off, Nexomis, a technological support and consultancy platform dedicated to the exploitation and enhancement of Omics data. Based on cutting-edge expertise in bioinformatics and NGS, as well as extensive skills in AI, mathematics and system administration, Nexomis is a solutions architect for computational biology. Its technological offering consists of three main services: the use of proven pipelines for rapid, high-quality analys...

We announce that the Canadian Intellectual Property Office and the European Patent Office have granted our patents for the repurposing of diltiazem as a modulator of the innate antiviral defense, and its combination with current antivirals targeting influenza viruses. The synergy between Virnext’s expertise in respiratory viruses, preclinical in vitro and in vivo infection models, and facilities, along with those of the LVMC at the Centre de recherche du CHU de Québec-Université Laval, has e...

She holds a two-year technical degree in biology and biochemical analysis, as well as a bachelor’s degree in genetic and cell biology. She is also certified to work in A1 and A2 level facilities. Romane recently graduated with a master’s degree in molecular and cellular biology with a specialization in infectiology from Université Claude Bernard Lyon 1. During her 6-month internship with our team, she studied host-virus interactions at the early stages of Respiratory Syncytial Virus infe...

Dear partners and network, We are pleased to announce the publication of our second newsletter, a retrospective of the significant milestones and key scientific achievements of the Technological Research Platform virnext and its spin-offs throughout 2023. Access the newsletter here: https://lnkd.in/dF9si9Jw Thank you in advance for your support and confidence by sharing this newsletter with your network....

CNRS (Centre National de la Recherche Scientifique) biology has selected the research program of our International Associated Laboratory, RESPIVIR, France - Canada, as part of the International Research Program 2023 call (IRP). Involving Université Laval, Université Claude Bernard Lyon 1 and our Technology Research Platform Virnext, RESPIVIR was created between Manuel Rosa-Calatrava's team and that of Guy Boivin LVMC at the Centre de recherche du CHU de Québec-Université Laval to conduct...

On December 13, the ceremony celebrated the contributions made by members of our university community to the reputation of Université Claude Bernard Lyon 1. The RESPIVIR France-Canada International Associate Laboratory, created in collaboration with Laval University and involving Virnext, has been selected for the ETOILE2023 call for proposals, which supports excellence in research and innovation in line with the university's strategic priorities. This support from UCBL1 for the internationa...